Lipoprotein receptors and atherogenic receptor-mediated mechanisms.
The liver plays a decisive role in the regulation of the plasma levels of atherogenic lipoproteins. The primary liver interaction site of chylomicron remnants and VLDL remnants (beta-VLDL) is still unidentified, whereas the subsequent cellular uptake is likely to be mediated in concert by the LDL receptor-related protein and the LDL receptor. The nature of the primary interaction site of remnants (remnant receptor) might be a liver-specific proteoglycan or a liver-specific protein. Atherogenic modified LDL can be recognized by a family of scavenger receptors. A newly identified 95 kDa protein forms the most likely candidate for mediating the in-vivo uptake of oxidized LDL from the circulation and may, therefore, protect the body against the presence of oxidized LDL in the blood compartment.
Division of Biopharmaceutics, Leiden-Amsterdam Center for Drug Research, Sylvius Laboratories, University of Leiden, The Netherlands.
T J
TJ
van Berkel
G J
GJ
Ziere
M K
MK
Bijsterbosch
J
J
Kuiper
D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism*; D002478:Cells, Cultured; D006801:Humans; D008099:Liver / Q000166:cytology / Q000378:metabolism; D011485:Protein Binding; D018110:Receptors, Lipoprotein / Q000378:metabolism*; D014407:Tumor Cells, Cultured
D018110:Receptors, Lipoprotein